Adma Biologics Inc. (ADMA)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Adma Biologics (ADMA) Up 43.3% Since Last Earnings Report: Can It Continue?
Adma Biologics (ADMA) reported earnings 30 days ago. What's next for the stock?
Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Adma Biologics (ADMA) Upgraded to Buy: Here's What You Should Know
Adma Biologics (ADMA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is ADMA Biologics (ADMA) Outperforming Other Medical Stocks This Year?
Here is how Adma Biologics (ADMA) and Cronos Group (CRON) have performed compared to their sector so far this year.
Adma Biologics (ADMA) Recently Broke Out Above the 200-Day Moving Average
After reaching an important support level, Adma Biologics (ADMA) could be a good stock pick from a technical perspective. ADMA surpassed resistance at the 200-day moving average, suggesting a long-term bullish trend.
ADMA Biologics: Why The Dip To $16 Resets The Buy Case
ADMA Biologics remains a Buy as Q3 results and 2026 guidance support a bullish long-term outlook. ADMA's Asceniv drives robust revenue and margin expansion, with 2026 revenue guided at $630M and EBITDA margin at 56%. Yield-enhanced manufacturing and facility expansion position ADMA for further growth, while SG-001 offers optionality beyond 2029.
Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Adma Biologics (ADMA) Just Flashed Golden Cross Signal: Do You Buy?
From a technical perspective, Adma Biologics (ADMA) is looking like an interesting pick, as it just reached a key level of support. ADMA recently overtook the 20-day moving average, and this suggests a short-term bullish trend.
Adma Biologics (ADMA) Crossed Above the 50-Day Moving Average: What That Means for Investors
Adma Biologics (ADMA) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ADMA broke through the 50-day moving average, which suggests a short-term bullish trend.
ADMA's Q3 Earnings Match Estimates, Revenues Beat on Strong Asceniv Sales
ADMA Biologics posts strong Q3 revenues and record Asceniv demand, but shares slip as higher taxes temper net income growth.
ADMA Biologics, Inc. (ADMA) Q3 2025 Earnings Call Transcript
ADMA Biologics, Inc. ( ADMA ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Adam Grossman - Co-Founder, President, CEO & Director Brad Tade - CFO & Treasurer Conference Call Participants Anthony Petrone - Mizuho Securities USA LLC, Research Division Rick Miller - Cantor Fitzgerald & Co., Research Division Gary Nachman - Raymond James & Associates, Inc., Research Division Presentation Operator Good afternoon, and welcome to the ADMA Biologics Third Quarter 2025 Financial Results and Business Update Conference Call on Wednesday, November 5 2025. [Operator Instructions] Please be advised that this call is being recorded at the company's request and will be available on the company's website approximately 2 hours following the end of the call.
Adma Biologics (ADMA) Q3 Earnings Match Estimates
Adma Biologics (ADMA) came out with quarterly earnings of $0.16 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.15 per share a year ago.
